Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

Inclusion Criteria: * Age \> 18 years. * Male or female subjects. * Have chronic heart failure defined as NYHA classification of II or III. * Be on a stable regimen of ACEI/ARB and/or beta-blocker 3 months prior to receiving study medication and are expected to remain on a stable HF medication regime throughout the duration of the trial. * Left ventricular ejection fraction (LVEF) of \< 35% as determined at screening by 2-D echocardiography. * Is able to understand and provide informed consent. * If subject has dilated cardiomyopathy, ischemic heart disease or corrected valvular heart disease, and had surgery to repair or replace value, the surgery must have been performed 3 months prior to receiving study medication and the surgical area is functioning normally. * Proper birth control must be used at least 3 weeks prior to the study (women only), during the infusion period of study drug (men and women), 4-weeks after study drug administration (men and women) and the remaining 11 months in the study follow-up (women). Women must have a negative pregnancy test at screening. * No greater than mild pericardial effusion \< 0.5 cm on echocardiography (roughly corresponds to \< 100 mL). * Have an implantable cardioverter-defibrillator (ICD). The ICD should have been implanted at least 3 months prior to receiving study medication. Patients should undergo interrogation of their ICDs between 1 and 7 days before randomization to drug for the previous thirty (30) days. This interrogati…